Crit Care:利尿剂有助于AKI重症患者成功停用CRRT?

2018-10-30 吴星 环球医学网

连续性肾脏替代疗法(CRRT)是重症医学科中重要的生命支持技术之一。2018年10月,发表在《Crit Care》的一项研究调查了,急性肾损伤(AKI)ICU患者利尿剂的使用与成功停用CRRT的相关性。

连续性肾脏替代疗法(CRRT)是重症医学科中重要的生命支持技术之一。2018年10月,发表在《Crit Care》的一项研究调查了,急性肾损伤(AKI)ICU患者利尿剂的使用与成功停用CRRT的相关性。

背景:尽管AKI重症患者积极使用CRRT,但是对于CRRT停用时是否使用利尿剂未达成一致。该研究评价了利尿剂对重症患者CRRT停用的影响。

方法:这项回顾性队列研究纳入1176例2009年~2014年停用CRRT后生存超过3天的成人患者。患者分组根据停用CRRT后3天内再次启用肾脏替代疗法或使用利尿剂。结局指标为停用CRRT后尿排出量(UO)和肾功能的变化。并分析成功停用CRRT的预测因素。

结果:CRRT停用组在停用CRRT前一天(d?1)的CRRT持续时间更短、利尿剂的使用更频繁,UO更多。利尿剂组停用CCRT后UO和血肌酐值升高有更多的增加。CRRT停用组持续呋塞米输注可更有效增加UO。多变量回归分析显示,较高的d?1 UO和利尿剂的使用是成功停用CRRT的显着预测因素。d?1 UO为125 ml/d是预测CRRT后使用利尿剂治疗的少尿患者成功停用CRRT的临界值。

结论:d?1 UO和积极利尿剂治疗与成功停用CRRT相关。通过促进有利的体液平衡,利尿剂疗法或有助于AKI重症患者停用CRRT,尤其是对于少尿的患者.

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=351735, encodeId=5a67351e35f3, content=学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Nov 06 13:16:32 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271948, encodeId=373812e19481b, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284047, encodeId=89be128404ee8, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508146, encodeId=c6711508146cf, content=<a href='/topic/show?id=3ab55283c4' target=_blank style='color:#2F92EE;'>#CRRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5283, encryptionId=3ab55283c4, topicName=CRRT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28ae9942466, createdName=LSJ114, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-06 13718711b3m

    学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=351735, encodeId=5a67351e35f3, content=学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Nov 06 13:16:32 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271948, encodeId=373812e19481b, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284047, encodeId=89be128404ee8, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508146, encodeId=c6711508146cf, content=<a href='/topic/show?id=3ab55283c4' target=_blank style='color:#2F92EE;'>#CRRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5283, encryptionId=3ab55283c4, topicName=CRRT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28ae9942466, createdName=LSJ114, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=351735, encodeId=5a67351e35f3, content=学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Nov 06 13:16:32 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271948, encodeId=373812e19481b, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284047, encodeId=89be128404ee8, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508146, encodeId=c6711508146cf, content=<a href='/topic/show?id=3ab55283c4' target=_blank style='color:#2F92EE;'>#CRRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5283, encryptionId=3ab55283c4, topicName=CRRT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28ae9942466, createdName=LSJ114, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=351735, encodeId=5a67351e35f3, content=学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Nov 06 13:16:32 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271948, encodeId=373812e19481b, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284047, encodeId=89be128404ee8, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508146, encodeId=c6711508146cf, content=<a href='/topic/show?id=3ab55283c4' target=_blank style='color:#2F92EE;'>#CRRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5283, encryptionId=3ab55283c4, topicName=CRRT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28ae9942466, createdName=LSJ114, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=351735, encodeId=5a67351e35f3, content=学习了,很实用的临床经验,涨知识,获益匪浅,感谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/02/27/c53a212859edcad4f60a54feffff50bb.jpg, createdBy=67cf1525321, createdName=13718711b3m, createdTime=Tue Nov 06 13:16:32 CST 2018, time=2018-11-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271948, encodeId=373812e19481b, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284047, encodeId=89be128404ee8, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341120, encodeId=3bab134112082, content=<a href='/topic/show?id=b97e223562' target=_blank style='color:#2F92EE;'>#AKI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2235, encryptionId=b97e223562, topicName=AKI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7482500171, createdName=ms4468361851264128, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508146, encodeId=c6711508146cf, content=<a href='/topic/show?id=3ab55283c4' target=_blank style='color:#2F92EE;'>#CRRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5283, encryptionId=3ab55283c4, topicName=CRRT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=28ae9942466, createdName=LSJ114, createdTime=Thu Nov 01 05:29:00 CST 2018, time=2018-11-01, status=1, ipAttribution=)]
    2018-11-01 LSJ114

相关资讯

乖乖用了利尿剂,但患者却抽筋了……

抽筋,“行话”叫肌肉痉挛,是一种极其不愉快的躯体体验,每个人一生中可能都出现过在甜美的睡眠中强行被肌肉“叫醒”的经历。

总结利尿剂的用药细节和4个经验教训实例!

利尿剂的故事 利尿剂是唯一能充分控制和有效消除液体潴留的药物,是急性心衰抢救中首选的药物,也是慢性心衰液体潴留患者标准治疗中必不可少的组成部分。合理使用利尿剂是其他治疗心衰药物取得成功的关键因素之一。

Circulation.:AHA 右心衰竭的评估和管理科学声明:应用利尿剂重要

近期,美国心脏协会(AHA)发布《右心衰竭的评估和管理科学声明》,对右心衰竭的病因、流行病学、病理生理学以及急慢性右心衰竭的管理进行了论述。

Hypertension:利尿剂对难治性高血压(RfHTN)也是束手无策!

难治性高血压(RfHTN)是抗高血压治疗失败中的一种极端表现,定义:采用5种及以上药物(包括长效利尿剂(噻嗪类)和盐皮质激素受体拮抗剂)仍不能有效控制血压。RfHTN是顽固性高血压(RHTN)的一种亚型,RHTN定义:采用3种及以上抗高血压药物(包括利尿剂)血压仍维持在135/85mmHg以上。RHTN一般是由持续性血管内液体潴留导致。目前尚不明确对于RfHTN,是否还存在其他致病机制。Aleja

入不敷出,利“干”见影,一文搞定心衰容量管理!

心力衰竭(简称心衰)本身不是一种疾病,而一组临床综合征,任何心血管疾病发展到晚期均可引起心衰。根据定义可以了解心衰是由各种原因导致心室收缩或舒张功能下降,病理生理学上表现为肺淤血和(或)体循环淤血,临床上表现为呼吸困难(肺淤血)、乏力(组织低灌注)以及外周水肿(液体潴留)等。

Osteoporos Int:噻嗪类利尿剂一箭双雕 既降压又预防骨质疏松?

骨质疏松症是世界范围内的主要慢性疾病之一,骨折作为骨质疏松症的一种严重不良后果,已成为一个主要的公共卫生问题。